Achieve Life Sciences, Inc.
Here’s whether Achieve Life Sciences, Inc. (ACHV) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Neutral.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); strong 1-year return of +141.7%; rising volume confirms the move (1.78x 30d avg). Concerns: 50-day MA is falling (-4.47% over 10 days); RSI 97 — overbought, elevated pullback risk; 3-month momentum negative (-12.5%). Currently 15.3% off its 52-week high. Score: +2/7.
ACHV is in a confirmed uptrend, trading above both its 50-day ($3.95) and 200-day ($3.83) moving averages. With an RSI of 96.6, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +141.7% compares to +35.1% for SPY (beat the market by 106.6%).